Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: A short-term study

Diana Iturralde, Richard F. Spaide, Catherine Meyerle, Jay M. Klancnik, Lawrence A. Yannuzzi, Yale L. Fisher, John Sorenson, Jason S. Slakter, K. Bailey Freund, Michael Cooney, Howard F. Fine

Research output: Contribution to journalArticle

Abstract

PURPOSE: To report the short term anatomic and visual acuity response after intravitreal injection of bevacizumab (Avastin, Genentech) in patients with macular edema due to central retinal vein occlusion (CRVO). METHODS: The authors conducted a retrospective study of patients with macular edema due to CRVO who were treated with at least one intravitreal injection of bevacizumab 1.25 mg in 0.05 mL. Patients underwent Snellen visual acuity testing, optical coherence tomography (OCT) imaging, and ophthalmoscopic examination at baseline and follow-up visits. RESULTS: There were 16 eyes of 15 consecutive patients with a mean age of 76.1 years (SD 9.8 years). Intravitreal triamcinolone had been previously administered to 9 patients, but all of these patients either had no improvement or had excessive intraocular pressure caused by the triamcinolone. The patients received a mean of 2.8 injections of bevacizumab per eye. No adverse events were observed, including endophthalmitis, clinically evident inflammation, increased intraocular pressure, retinal tears, retinal detachment, or thromboembolic events in any patient. The mean central macular thickness at baseline was 887 μm and decreased to a mean of 372 μm at month 1 (P <0.001). The mean baseline acuity was 20/600 (logMAR = 1.48) and the mean acuity at month 1 was 20/200 (logMAR = 1.05), a difference that was highly significant (P = 0.001). At last follow-up, a mean of 3 months after the first injection, the mean visual acuity was 20/138 (logMAR = 0.84), which was significantly better than baseline (P <0.001). Visual acuity improvement, defined as a halving of the visual angle, was seen in 14 of the 16 eyes. CONCLUSION: Initial treatment results of patients with macular edema secondary to CRVO did not reveal any short-term safety concerns. Intravitreal bevacizumab resulted in a significant decrease in macular edema and improvement in visual acuity. The number of patients in this pilot study was limited and the follow-up is too short to make any specific treatment recommendations, but the favorable short-term results suggest further study is needed.

Original languageEnglish (US)
Pages (from-to)279-284
Number of pages6
JournalRetina
Volume26
Issue number3
DOIs
StatePublished - Mar 2006
Externally publishedYes

Fingerprint

Retinal Vein
Retinal Vein Occlusion
Macular Edema
Visual Acuity
Therapeutics
Triamcinolone
Intravitreal Injections
Intraocular Pressure
Bevacizumab
Retinal Perforations
Injections
Endophthalmitis
Optical Coherence Tomography
Retinal Detachment
Retrospective Studies
Inflammation
Safety

Keywords

  • Bevacizumab
  • Central retinal vein occlusion
  • Fluorescein angiography
  • Macular edema
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems

Cite this

Iturralde, D., Spaide, R. F., Meyerle, C., Klancnik, J. M., Yannuzzi, L. A., Fisher, Y. L., ... Fine, H. F. (2006). Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: A short-term study. Retina, 26(3), 279-284. https://doi.org/10.1097/00006982-200603000-00005

Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion : A short-term study. / Iturralde, Diana; Spaide, Richard F.; Meyerle, Catherine; Klancnik, Jay M.; Yannuzzi, Lawrence A.; Fisher, Yale L.; Sorenson, John; Slakter, Jason S.; Freund, K. Bailey; Cooney, Michael; Fine, Howard F.

In: Retina, Vol. 26, No. 3, 03.2006, p. 279-284.

Research output: Contribution to journalArticle

Iturralde, D, Spaide, RF, Meyerle, C, Klancnik, JM, Yannuzzi, LA, Fisher, YL, Sorenson, J, Slakter, JS, Freund, KB, Cooney, M & Fine, HF 2006, 'Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: A short-term study', Retina, vol. 26, no. 3, pp. 279-284. https://doi.org/10.1097/00006982-200603000-00005
Iturralde, Diana ; Spaide, Richard F. ; Meyerle, Catherine ; Klancnik, Jay M. ; Yannuzzi, Lawrence A. ; Fisher, Yale L. ; Sorenson, John ; Slakter, Jason S. ; Freund, K. Bailey ; Cooney, Michael ; Fine, Howard F. / Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion : A short-term study. In: Retina. 2006 ; Vol. 26, No. 3. pp. 279-284.
@article{ca49cd645adb4269b2124c317904ff17,
title = "Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: A short-term study",
abstract = "PURPOSE: To report the short term anatomic and visual acuity response after intravitreal injection of bevacizumab (Avastin, Genentech) in patients with macular edema due to central retinal vein occlusion (CRVO). METHODS: The authors conducted a retrospective study of patients with macular edema due to CRVO who were treated with at least one intravitreal injection of bevacizumab 1.25 mg in 0.05 mL. Patients underwent Snellen visual acuity testing, optical coherence tomography (OCT) imaging, and ophthalmoscopic examination at baseline and follow-up visits. RESULTS: There were 16 eyes of 15 consecutive patients with a mean age of 76.1 years (SD 9.8 years). Intravitreal triamcinolone had been previously administered to 9 patients, but all of these patients either had no improvement or had excessive intraocular pressure caused by the triamcinolone. The patients received a mean of 2.8 injections of bevacizumab per eye. No adverse events were observed, including endophthalmitis, clinically evident inflammation, increased intraocular pressure, retinal tears, retinal detachment, or thromboembolic events in any patient. The mean central macular thickness at baseline was 887 μm and decreased to a mean of 372 μm at month 1 (P <0.001). The mean baseline acuity was 20/600 (logMAR = 1.48) and the mean acuity at month 1 was 20/200 (logMAR = 1.05), a difference that was highly significant (P = 0.001). At last follow-up, a mean of 3 months after the first injection, the mean visual acuity was 20/138 (logMAR = 0.84), which was significantly better than baseline (P <0.001). Visual acuity improvement, defined as a halving of the visual angle, was seen in 14 of the 16 eyes. CONCLUSION: Initial treatment results of patients with macular edema secondary to CRVO did not reveal any short-term safety concerns. Intravitreal bevacizumab resulted in a significant decrease in macular edema and improvement in visual acuity. The number of patients in this pilot study was limited and the follow-up is too short to make any specific treatment recommendations, but the favorable short-term results suggest further study is needed.",
keywords = "Bevacizumab, Central retinal vein occlusion, Fluorescein angiography, Macular edema, Vascular endothelial growth factor",
author = "Diana Iturralde and Spaide, {Richard F.} and Catherine Meyerle and Klancnik, {Jay M.} and Yannuzzi, {Lawrence A.} and Fisher, {Yale L.} and John Sorenson and Slakter, {Jason S.} and Freund, {K. Bailey} and Michael Cooney and Fine, {Howard F.}",
year = "2006",
month = "3",
doi = "10.1097/00006982-200603000-00005",
language = "English (US)",
volume = "26",
pages = "279--284",
journal = "Retina",
issn = "0275-004X",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion

T2 - A short-term study

AU - Iturralde, Diana

AU - Spaide, Richard F.

AU - Meyerle, Catherine

AU - Klancnik, Jay M.

AU - Yannuzzi, Lawrence A.

AU - Fisher, Yale L.

AU - Sorenson, John

AU - Slakter, Jason S.

AU - Freund, K. Bailey

AU - Cooney, Michael

AU - Fine, Howard F.

PY - 2006/3

Y1 - 2006/3

N2 - PURPOSE: To report the short term anatomic and visual acuity response after intravitreal injection of bevacizumab (Avastin, Genentech) in patients with macular edema due to central retinal vein occlusion (CRVO). METHODS: The authors conducted a retrospective study of patients with macular edema due to CRVO who were treated with at least one intravitreal injection of bevacizumab 1.25 mg in 0.05 mL. Patients underwent Snellen visual acuity testing, optical coherence tomography (OCT) imaging, and ophthalmoscopic examination at baseline and follow-up visits. RESULTS: There were 16 eyes of 15 consecutive patients with a mean age of 76.1 years (SD 9.8 years). Intravitreal triamcinolone had been previously administered to 9 patients, but all of these patients either had no improvement or had excessive intraocular pressure caused by the triamcinolone. The patients received a mean of 2.8 injections of bevacizumab per eye. No adverse events were observed, including endophthalmitis, clinically evident inflammation, increased intraocular pressure, retinal tears, retinal detachment, or thromboembolic events in any patient. The mean central macular thickness at baseline was 887 μm and decreased to a mean of 372 μm at month 1 (P <0.001). The mean baseline acuity was 20/600 (logMAR = 1.48) and the mean acuity at month 1 was 20/200 (logMAR = 1.05), a difference that was highly significant (P = 0.001). At last follow-up, a mean of 3 months after the first injection, the mean visual acuity was 20/138 (logMAR = 0.84), which was significantly better than baseline (P <0.001). Visual acuity improvement, defined as a halving of the visual angle, was seen in 14 of the 16 eyes. CONCLUSION: Initial treatment results of patients with macular edema secondary to CRVO did not reveal any short-term safety concerns. Intravitreal bevacizumab resulted in a significant decrease in macular edema and improvement in visual acuity. The number of patients in this pilot study was limited and the follow-up is too short to make any specific treatment recommendations, but the favorable short-term results suggest further study is needed.

AB - PURPOSE: To report the short term anatomic and visual acuity response after intravitreal injection of bevacizumab (Avastin, Genentech) in patients with macular edema due to central retinal vein occlusion (CRVO). METHODS: The authors conducted a retrospective study of patients with macular edema due to CRVO who were treated with at least one intravitreal injection of bevacizumab 1.25 mg in 0.05 mL. Patients underwent Snellen visual acuity testing, optical coherence tomography (OCT) imaging, and ophthalmoscopic examination at baseline and follow-up visits. RESULTS: There were 16 eyes of 15 consecutive patients with a mean age of 76.1 years (SD 9.8 years). Intravitreal triamcinolone had been previously administered to 9 patients, but all of these patients either had no improvement or had excessive intraocular pressure caused by the triamcinolone. The patients received a mean of 2.8 injections of bevacizumab per eye. No adverse events were observed, including endophthalmitis, clinically evident inflammation, increased intraocular pressure, retinal tears, retinal detachment, or thromboembolic events in any patient. The mean central macular thickness at baseline was 887 μm and decreased to a mean of 372 μm at month 1 (P <0.001). The mean baseline acuity was 20/600 (logMAR = 1.48) and the mean acuity at month 1 was 20/200 (logMAR = 1.05), a difference that was highly significant (P = 0.001). At last follow-up, a mean of 3 months after the first injection, the mean visual acuity was 20/138 (logMAR = 0.84), which was significantly better than baseline (P <0.001). Visual acuity improvement, defined as a halving of the visual angle, was seen in 14 of the 16 eyes. CONCLUSION: Initial treatment results of patients with macular edema secondary to CRVO did not reveal any short-term safety concerns. Intravitreal bevacizumab resulted in a significant decrease in macular edema and improvement in visual acuity. The number of patients in this pilot study was limited and the follow-up is too short to make any specific treatment recommendations, but the favorable short-term results suggest further study is needed.

KW - Bevacizumab

KW - Central retinal vein occlusion

KW - Fluorescein angiography

KW - Macular edema

KW - Vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=33646446084&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646446084&partnerID=8YFLogxK

U2 - 10.1097/00006982-200603000-00005

DO - 10.1097/00006982-200603000-00005

M3 - Article

C2 - 16508427

AN - SCOPUS:33646446084

VL - 26

SP - 279

EP - 284

JO - Retina

JF - Retina

SN - 0275-004X

IS - 3

ER -